Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 70.47
Day High 72.31
Open:72.02
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports+

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

AHF: 'Gilead: We Told You So on COVID Drug Pricing!'
- BusinessWire - 41 minutes ago
BusinessWire - CMTX
41 minutes ago
--In May, AIDS Healthcare Foundation demanded that the drug company price remdesivir, the newly approved drug for treating COVID-19--which Gilead had developed years earlier with $70M in government funding as a possible Ebola treatment--at one dollar per day per patient
Gene Therapy Market to Reach USD 35.67 Billion by 2027; Rising Prevalence of Cancer to Bolster Growth, says Fortune Business Insights(TM)
- GlobeNewswire - Tue Aug 4, 9:31AM CDT
GlobeNewswire - CMTX
Tue Aug 4, 9:31AM CDT
The global gene therapy market is set to gain momentum from the rising incidence of different types of cancer. The field of this therapy is undergoing several technological advancements that would help in treating cancer in those patients who are at high risks of getting affected by this disease through genetic mutations. Fortune Business Insights(TM) provided this information in a new report, titled, "Gene Therapy Market Size, Share & COVID-19 Impact Analysis, By Application (Oncology, Neurology, and Others), By Vector Type (Viral and Non-viral), By Distribution Channel (Hospitals, Clinics, and Others), and Regional Forecast, 2020-2027." The report further mentions that the market size was USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, exhibiting a CAGR of 33.6% during the forecast period.
Growing Expectations COVID Vaccine Could Be Ready By End Of Year
- PR Newswire - PRF - Tue Aug 4, 7:45AM CDT
PR Newswire - PRF - CMTX
Tue Aug 4, 7:45AM CDT
, /PRNewswire/ -- It seems lately, that news on a vaccine (or vaccines) for the global health crisis, project new possibilities moving quickly to the final solution.  The number of vaccines in development seems to be growing daily. Recently, , MD, director of the National Institute of Allergy and Infectious Diseases, testified in Congress, saying that it was a definitely a possibility would have an effective vaccine against COVID-19 by early next year. An  on his testimony from the Center for Infectious Disease Research and Policy added: "His optimism comes on the same day Operation Warp Speed, the US's COVID-19 vaccine program, announced its biggest agreement yet: $2.1 billion to Sanofi Pasteur to supply the US government with 100 million doses of its experimental coronavirus vaccine. Sanofi is working with GlaxoSmithKline on a vaccine clinical trial planned for September."  Active biotech companies with recent developments include: (OTCQB: NBIO), (NASDAQ: NVAX), (NASDAQ: INO), (NASDAQ: MRNA), (NASDAQ: GILD.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 68.52 +3.44% increase
on 07/31/20
Period Open:76.35
Price movement based on the high, low and last over the given period.
78.94 -10.21% decrease
on 07/20/20
-5.47 (-7.16%) decrease
since 07/02/20
3-Month 68.52 +3.44% increase
on 07/31/20
Period Open:80.25
Price movement based on the high, low and last over the given period.
80.92 -12.41% decrease
on 05/11/20
-9.37 (-11.68%) decrease
since 05/04/20
52-Week 60.89 +16.41% increase
on 10/03/19
Period Open:64.95
Price movement based on the high, low and last over the given period.
85.97 -17.55% decrease
on 03/19/20
+5.93 (+9.13%) increase
since 08/02/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies